AP-188 DMT being developed as a possible treatment of ischemic stroke and for post-stroke rehabilitation

Algernon has started a clinical research program for stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family.

Algernon plans to be the first Company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.

Compound DMT
Country Canada
Visit trial
Status Active, not recruiting
Results Published
Start date 01 December 2021
End date 01 June 2022
Chance of happening 100%
Phase Phase I
Design Open
Type Interventional
Participants 20
Sex All
Therapy No

Trial Details

The Company’s decision to investigate DMT and move it into human trials for stroke is based on multiple independent, positive preclinical studies demonstrating that DMT helps promote neurogenesis as well as structural and functional neural plasticity. These are key factors involved in the brain’s ability to form and reorganize synaptic connections, which are needed for healing following a brain injury. A recently published preclinical study in an animal model for stroke, showed that rats treated with DMT recovered motor function more quickly and to a greater extent, and also exhibited lower lesion volumes when compared to control group animals that did not receive DMT. Key data from the study achieved statistical significance.

NCT Number PA6

Sponsors & Collaborators

Algernon Pharmaceuticals
Algernon is a clinical stage pharmaceutical company that is developing novel psychedelic molecules (based on DMT) for the treatment of stroke-related dysfunction.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.